Famed boot manufacturer, Dr. Martens, anticipates a substantial financial impact from US tariffs this year. The company, known for its iconic yellow-stitched boots, has shifted its production base to Vietnam due to increased import duties resulting from the trade tensions between the US and China.

Dr. Martens expects a significant negative effect on its profits due to tariffs, with an estimated impact in the high single-digit million-pound range for the year. Despite this setback, the company remains confident in achieving its full-year profit forecasts of £53 million to £60 million, excluding the tariff-related losses.

The market announcement led to a more than 10% drop in Dr. Martens’ share price during early trading. To mitigate the tariff costs, the company plans strategic measures, including stringent cost control, flexible sourcing strategies, and adjustments to US pricing policies starting from the next fiscal year.

In its recent update, Dr. Martens disclosed that it aims to completely offset the tariff impact from the 2026/27 financial year onwards. The company’s half-year results showed a reduction in losses to £11 million, with a slight sales increase to £327.3 million for the first half of the year.

CEO Ije Nwokorie emphasized the brand’s strength, citing a 33% rise in shoe volumes and successful launches of new products. Despite market uncertainties and consumer caution, Dr. Martens remains optimistic about its future plans and the ongoing progress in its business strategies.

Investment director Russ Mould acknowledged the company’s efforts to enhance profitability, noting improvements in product pricing and performance in key markets. However, market response indicated some investor disappointment, reflected in the initial decline in share value during trading.